LONDON, July 20 --

There has been a recent upsurge in Merger Acquisition (MA) activities in the
pharmaceutical and biotechnology space. While the economic downturn and related
credit crunch has had an impact, this alone cannot account for the recent MA
mania, which has including four mega MAs in the first half of 2009.


The real intention behind these mergers remains a question, as past mergers
have not yielded substantial value addition in terms of RD productivity, says
Frost Sullivan Senior Research Analyst Ranjith Gopinathan.

To look at these Mergers Acquisitions in the Pharmaceutical and Biotechnology
industry, the Healthcare Group at Frost Sullivan will be hosting a
complimentary Analyst Briefing Presentation on Tuesday, 28th July 2009, at 2
p.m. BST/ 1 p.m. GMT.

Highlights of this briefing will include an analysis of the factors
contributing to the increasing consolidation in the market, the impact of the
economic downturn, as well as funding sources for biotech companies. The
briefing will also look at key restraints for MA activities in the
pharma-biotech industry and provide a future MA outlook. The discussion will
benefit venture capitalists, investment banks, pharma and biotech companies as
well as academic institutions.

The global downturn’s detrimental impact on funding availability coupled
with an average 30 per cent decline in the value of biotech firms, means that
outright acquisitions rather than complex licensing deals are an attractive
proposition, concludes Gopinathan.

To participate in this briefing, please email Patrick Cairns at with the following information: your full name, company
name, title, telephone number, e-mail address, city, state, and country. Upon
receipt of the above information, a registration link will be emailed to you.

About Frost Sullivan:

Frost Sullivan, the Growth Partnership Company, partners with clients to
accelerate their growth. The company’s TEAM Research, Growth Consulting
and Growth Team Membership empower clients to create a growth-focused culture
that generates, evaluates and implements effective growth strategies. Frost
Sullivan employs over 45 years of experience in partnering with Global 1000
companies, emerging businesses and the investment community from more than 35
offices on six continents. For more information about Frost Sullivan’s
Growth Partnerships, visit

Contact: Patrick Cairns Corporate Communications P: +27-18-468-2315 M:
+27-83-258-4219 E:

SOURCE: Frost SOURCE: Sullivan

Patrick Cairns, Corporate Communications of Frost Sullivan, +27-18-468-2315,
mobile, +27-83-258-4219, Logo: